Source:http://linkedlifedata.com/resource/pubmed/id/10674880
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2000-4-7
|
pubmed:abstractText |
A potential advantage of primary over adjuvant chemotherapy in breast cancer survival had been proposed on theoretical grounds. In 1994, early results of the S6-trial comparing primary chemotherapy vs. adjuvant chemotherapy for operable breast cancer in 390 premenopausal patients had shown significant improvement in survival of the primary chemotherapy arm (p = 0.04). An updated analysis conducted in 1995 showed the disappearance of this difference between the two arms (p = 0.18). In the present analysis, we investigated the potential short and long-term benefits attributable to primary chemotherapy by applying weighted logrank tests designed to assess specifically these effects. Results were compared to those obtained with the classical logrank test. At a median follow-up of 105 months, a significant short-term survival benefit (p = 0.02) in favor of the primary chemotherapy has been shown. However, no long-term survival benefit (p = 0.36) could be documented. The classical logrank test had revealed no significant difference (p = 0.24) between the two groups but the proportional hazard assumption being rejected (p = 0.04), the efficiency of this test can be questioned. Results using the present analysis suggested that primary chemotherapy delayed early death rates, without significantly modifying long-term event rates. It emphasizes that a short-term effect which is not necessarily associated with a long-term benefit may be seen at an early evaluation and disappear later on.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0167-6806
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
58
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
151-6
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10674880-Antineoplastic Agents,
pubmed-meshheading:10674880-Breast Neoplasms,
pubmed-meshheading:10674880-Chemotherapy, Adjuvant,
pubmed-meshheading:10674880-Female,
pubmed-meshheading:10674880-Follow-Up Studies,
pubmed-meshheading:10674880-France,
pubmed-meshheading:10674880-Humans,
pubmed-meshheading:10674880-Middle Aged,
pubmed-meshheading:10674880-Proportional Hazards Models,
pubmed-meshheading:10674880-Randomized Controlled Trials as Topic,
pubmed-meshheading:10674880-Survival Analysis,
pubmed-meshheading:10674880-Time Factors
|
pubmed:year |
1999
|
pubmed:articleTitle |
Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial.
|
pubmed:affiliation |
Department of Biostatistics, Curie Institute, Paris, France.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|